MedTrace Logo

Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma

NCT06557512 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2026-05-18

No results posted yet for this study

Summary

This clinical trial tests the safety and effectiveness of hypofractionated stereotactic radiosurgery for treating patients who have undergone surgical resection for grade II meningiomas or grade I meningiomas that have come back after a period of improvement (recurrent). Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Stereotactic radiosurgery is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Hypofractionated stereotactic radiosurgery may be safe, tolerable, and effective in treating patients with grade II or recurrent grade I meningiomas after surgical resection.

Conditions

  • Meningioma
  • Meningioma, Malignant
  • Recurrent Meningioma

Interventions

RADIATION

Hypofractionated Stereotactic Radiosurgery (SRS)

Undergo Hypofractionated Stereotactic Radiosurgery

PROCEDURE

Magnetic Resonance Imaging (MRI)

Undergo MRI

PROCEDURE

Computed Tomography (CT)

Undergo CT imaging

Sponsors & Collaborators

Principal Investigators

  • William Chen, MD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-13
Primary Completion
2029-09-30
Completion
2029-09-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06557512 on ClinicalTrials.gov